Avicanna is a Canadian commercial-stage biopharmaceutical company established in research, development, and commercialization of evidence-based cannabinoid products for the global medical and pharmaceutical market segments.
Commercial Products & Pipeline
In Development and Registration Stage
Medical Cannabis & Wellness Products
Marketed under the RHO Phyto™ brand
The portfolio contains a diverse range of formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids such as cannabidiol (“CBD”), cannabigerol (“CBG”), and tetrahydrocannabinol (“THC”).
The formulary is supported by ongoing consumer, patient, and medical community education and training including https://www.avicanna.com/avicenna-academy.
The brand is currently available nationwide to patients in medical channels across Canada including MyMedi.ca launched August 2023. It is also accessible through several other medical institutions including The University Health Network (“UHN”) and the Odette Cancer Centre pharmacy of Sunnybrook Health Science Centre, a major hospital group in Canada. The products are also found in Canadian adult-use sales channels through provincial retailers in five provinces including Ontario, Alberta, British Columbia, New Brunswick, Manitoba, and Saskatchewan.
Pharmaceutical Preparation and Pipeline of Proprietary Drug Candidates
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization.
These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
MyMedi.ca- Medical Cannabis Care Platform
Industry leading scientific platform and intellectual property
Setting the Standard in the cannabinoid industry with advanced and evidence based products
R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano particle formulations.
Health Canada Cannabis
Research Licenses to Avicanna
or Institutional Collaborators